---
title: "Edgewise Therapeutics Sells Muscular Dystrophy Assets to Servier"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292519214.md"
description: "Edgewise Therapeutics completed the sale of its sevasemten compound and muscular dystrophy business to Servier Pharmaceuticals for up to $2.65 billion. The deal transfers all rights and staff to Servier, strengthening Edgewise's balance sheet and allowing it to focus on cardiovascular assets. Analysts rate EWTX as a Buy with a $51 price target, while TipRanks' AI suggests Neutral due to mixed fundamentals despite the strategic boost from the asset sale."
datetime: "2026-07-13T17:28:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292519214.md)
  - [en](https://longbridge.com/en/news/292519214.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292519214.md)
---

# Edgewise Therapeutics Sells Muscular Dystrophy Assets to Servier

### TipRanks Welcomes a New ETF – NYSE:RANK

-   TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
-   RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.

Edgewise Therapeutics ( (EWTX) ) just unveiled an announcement.

On July 10, 2026, Edgewise Therapeutics completed the sale of its sevasemten compound and muscular dystrophy business to Servier Pharmaceuticals for $1.55 billion in upfront cash and up to $1.1 billion in milestone payments, for potential total consideration of $2.65 billion. The deal transfers all sevasemten rights, IP, data and core program staff to Servier, which aims to build a rare neurology franchise while continuing late-stage development in Becker and Duchenne muscular dystrophy.

Announced publicly on July 13, 2026, the transaction significantly strengthens Edgewise’s balance sheet and consolidates its strategy as a cardiovascular-focused company built around lead assets EDG-7500, EDG-15400 and EDG-003. Edgewise expects the upfront proceeds, combined with existing cash, to fully fund EDG-7500 through potential approval and support broader cardiovascular pipeline expansion, while Servier gains a late-stage, regulatorily de-risked muscular dystrophy asset with orphan and rare pediatric designations and ongoing pivotal trials.

The most recent analyst rating on (EWTX) stock is a Buy  
with a $51.00 price target.  
To see the full list of analyst forecasts on Edgewise Therapeutics stock,  
see the EWTX Stock Forecast page.

**Spark’s Take on EWTX Stock**

According to Spark, TipRanks’ AI Analyst, EWTX is a Neutral.

The score is primarily driven by mixed financial fundamentals: a strong, low-debt balance sheet is a meaningful positive, but it is offset by being pre-revenue with large, persistent losses and heavy cash burn. Technically, the stock is in a strong uptrend, though momentum indicators suggest it may be overextended. Valuation remains weak due to negative earnings and no dividend support, while the recent asset-sale event provides a significant near-term balance-sheet and strategic boost.

To see Spark’s full report on EWTX stock,  
click here.

**More about Edgewise Therapeutics**

Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in novel, muscle-targeted small-molecule therapeutics, with a growing focus on cardiovascular diseases. The Boulder, Colo.-based firm is advancing a pipeline aimed at significant unmet needs such as hypertrophic cardiomyopathy, heart failure with preserved ejection fraction and other serious cardiovascular and cardiometabolic conditions.

**Average Trading Volume:** 1,474,763

**Technical Sentiment Signal:** Buy

**Current Market Cap:** $4.89B

For a thorough assessment of EWTX stock, go to TipRanks’ Stock Analysis page.

### Related Stocks

- [EWTX.US](https://longbridge.com/en/quote/EWTX.US.md)
- [RANK.US](https://longbridge.com/en/quote/RANK.US.md)

## Related News & Research

- [Joanne Donovan Sells 2,919 Shares of Edgewise Therapeutics (NASDAQ:EWTX) Stock](https://longbridge.com/en/news/295978695.md)
- [Insider Selling: Edgewise Therapeutics (NASDAQ:EWTX) Insider Sells 5,901 Shares](https://longbridge.com/en/news/295977544.md)
- [3 arguments for and against AI watermarks](https://longbridge.com/en/news/296205500.md)
- [The AI boom has echoes of Enron — but that might be okay, a tech guru says](https://longbridge.com/en/news/296021200.md)
- [Originalis AI Founding Engineer Ujjwal Jain Unveils AI System Processing Over 645,000 VC Email Threads](https://longbridge.com/en/news/296065185.md)